Reprieve Cardiovascular Nabs $42M to Expand Intelligent Fluid Management for Heart Failure

What You Should Know:

– Reprieve Cardiovascular, a pioneer in personalized fluid management for acute decompensated heart failure (ADHF) emerges from stealth launching with $42M in Series A financing round.

– The Series A round was co-led by Lightstone Ventures and Sante Ventures with participation from Deerfield Management, Genesis Capital, and Arboretum Ventures, will fuel the company’s clinical development programs and accelerate its mission to improve patient outcomes and reduce hospital readmissions for ADHF patients.

Addressing a Critical Need

Over 6.7 million Americans suffer from heart failure, with ADHF exacerbations leading to over a million hospital admissions annually. Frequent readmissions and prolonged hospital stays pose significant burdens on patients, healthcare systems, and costs. Reprieve’s intelligent fluid management system aims to address this critical need.

Reprieve System: A Personalized Approach to Fluid Management

Reprieve’s groundbreaking technology offers a personalized solution by continuously monitoring patients’ physiological parameters like urine output. This data is used to automatically adjust diuretic dosing and fluid replacement, aiming to safely and efficiently remove excess fluid while optimizing patient comfort and outcomes.

This personalized approach offers potential benefits such as:

– Improved patient outcomes

– Reduced hospital readmissions

– Shorter hospital stays

– Enhanced patient comfort

– Clinical Progress and Future Plans:

FASTR Trial Pilot

Reprieve is currently conducting the FASTR Trial, a pilot study comparing its system to traditional diuretic therapy. The company also plans to launch a pivotal trial soon. The Series A funding will enable them to advance these clinical programs, refine their technology, and prepare for commercialization.

“Today, the standard of care for heart failure patient fluid removal is diuretics. Originally approved 60 years ago, diuretics remain the primary treatment option but can be difficult to administer optimally without real-time patient information,” said Mark Pacyna, chief executive officer of Reprieve Cardiovascular. Pacyna continued, “Reprieve Cardiovascular is bringing intelligent decongestion management to heart failure patients. The Reprieve System provides physicians and care teams added visibility and control throughout treatment.”